Rinatabart sesutecan (Rina-S®) in advanced ovarian cancer and advanced or recurrent endometrial cancer: Results from dose-optimization cohorts in the phase 1/2 RAINFOL™-01 study
Publication date: Available online 9 November 2026 Source: International Journal of Gynecological Cancer Author(s): Elizabeth K. Lee, Oladapo Yeku, Justin Call, Debra L. Richardson, Noelle Cloven, Andrea Jewell, Leigh Seamon, Lyndsay J. Willmott, Gottfried E. Konecny, Douglas Orr, Jessica Thomes Pepin, Xiaohua Wu, Ian Anderson, Joseph Buscema, Ramez N. Eskander, Cara Mathews, Anton Melnyk, Alexander Spira, Biyi Shen, Janelle Croissette
Rinatabart sesutecan (Rina-S®) in advanced ovarian cancer and advanced or recurrent endometrial cancer: Results from dose-optimization cohorts in the phase 1/2 RAINFOL™-01 study. // International Journal of Gynecological Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1048891X26012144?dgcid=rss_sd_all
Rinatabart sesutecan (Rina-S®) in advanced ovarian cancer and advanced or recurrent endometrial cancer: Results from dose-optimization cohorts in the phase 1/2 RAINFOL™-01 study. International Journal of Gynecological Cancer. https://www.sciencedirect.com/science/article/pii/S1048891X26012144?dgcid=rss_sd_all
“Rinatabart sesutecan (Rina-S®) in advanced ovarian cancer and advanced or recurrent endometrial cancer: Results from dose-optimization cohorts in the phase 1/2 RAINFOL™-01 study.” International Journal of Gynecological Cancer.
@article{article49528,
title = {Rinatabart sesutecan (Rina-S®) in advanced ovarian cancer and advanced or recurrent endometrial cancer: Results from dose-optimization cohorts in the phase 1/2 RAINFOL™-01 study},
journal = {International Journal of Gynecological Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1048891X26012144?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment